Previous 10 | Next 10 |
Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidate Demonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition ...
Bolt Biotherapeutics (NASDAQ:BOLT): Q3 GAAP EPS of -$0.63 beats by $0.02. Revenue of $0.8M beats by $0.3M. Press Release Cash, cash equivalents, and marketable securities were $290.5M as of September 30, 2021, compared to $310.9M as of June 30, 2021. Bolt Biotherapeutics expects this cas...
–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 –Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, C...
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy...
REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune...
Today, we take our first look at Bolt Biotherapeutics, a small developmental firm focused on cancer immunotherapeutics and myeloid biology. The company just came public earlier this year but already is deep in 'Busted IPO' territory. A full investment analysis follows in the parag...
Several people in the U.K. are vocal about their experience with taxi apps such as Uber Inc. ( NYSE: UBER ) and Bolt Biotherapeutics ( NASDAQ: BOLT ). A section of users told CNBC that the apps did not connect them to a chauffeur. As a result, they were late for a meeting or lef...
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syst...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Bolt Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approx...